Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era
International experts set out how to diagnose Erdheim-Chester disease, which scans and mutation tests to do, and when to use BRAF and MEK inhibitors, interferon or other drugs.
Overview
Consensus recommendations from an international group of histiocytosis specialists covering the clinical features, imaging (whole-body PET-CT, cardiac and brain MRI), biopsy and molecular testing (BRAF V600E and other MAPK pathway alterations), the decision to treat, and therapy: BRAF inhibitors for BRAF-mutant disease, MEK inhibitors for BRAF wild-type disease, interferon alfa and other options, with guidance on monitoring and long-term management.
It updates the 2014 recommendations for the targeted therapy era.
The diagnostic and treatment rows on the Erdheim-Chester page follow these recommendations.
- Expert consensus in a disease with a few hundred reported cases; randomised evidence does not exist.
- Optimal duration of targeted therapy remains unknown.
Similar pages
not linked directly; found by shared links- Key paperVE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis
Shares Erdheim-Chester disease, Vemurafenib.
- Key paperRevised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Shares Blood, Erdheim-Chester disease.
- Key paperConsensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Shares Blood, Cobimetinib.
- PersonGrant McArthur
Shares Cobimetinib, Vemurafenib.
- TrialIMspire150
Shares Cobimetinib, Vemurafenib.
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Cobimetinib, Vemurafenib.
- TrialcoBRIM
Shares Cobimetinib, Vemurafenib.
- CancerErdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms
Shares Interferon alfa-2a/2b, Erdheim-Chester disease, Cobimetinib, Vemurafenib.